BRACAnalysis CDx is an FDA-approved companion diagnostic test for germline BRCA1 and BRCA2 mutations intended to be used as an aid in treatment decision making for LynparzaTM (olaparib), a PARP inhibitor.1
Myriad myRisk® Hereditary Cancer is a 28-gene panel that helps to determine a patient’s risk by evaluating a number of hereditary cancer syndromes, with focus on eight primary cancer sites.
COLARIS® testing assesses a person’s risk of developing hereditary colorectal cancer and a woman’s risk of developing hereditary uterine/endometrial cancer by detecting disease-causing mutations in the MLH1, MSH2, MSH6 and PMS2 genes.
COLARIS AP ® testing assesses a person’s risk of developing hereditary colorectal polyps and cancer by detecting mutations in the APC and MYH genes.
MELARIS® testing assesses a person’s risk of developing hereditary melanoma by detecting inherited mutations in the p16 gene (also called CDKN2A or INK4A ).
PANEXIA® testing assesses a person’s risk of developing hereditary pancreatic cancer by analyzing the PALB2 and BRCA2 genes, which are most commonly mutated in families with hereditary pancreatic cancer.
Myriad myPlan® Lung Cancer is a molecular diagnostic test that measures the expression levels of cell cycle progression genes to provide an accurate assessment of cancer aggressiveness in early-stage non-small cell lung cancer.
Myriad myPath™ Melanoma is a unique molecular diagnostic test that analyzes 23 genes to assist in the timely and accurate diagnosis of melanoma.
Prolaris® is a molecular diagnostic test that measures the expression level of genes involved with tumor proliferation to predict disease outcome. Prolaris® can be used in conjunction with other clinical parameters to determine prostate cancer aggressiveness.
Vectra® DA is a multi-biomarker molecular blood test that simultaneously measures 12 key biomarkers to provide an objective and reproducible measure of rheumatoid arthritis (RA) disease activity.
1 BRACAnalysis CDx™ is an in vitro diagnostic device intended for the qualitative detection and classification of variants in the protein coding regions and intron/exon boundaries of the BRCA1 and BRCA2 genes using genomic DNA obtained from whole blood specimens collected in EDTA. Single nucleotide variants and small insertions and deletions (indels) are identified by polymerase chain reaction (PCR) and Sanger sequencing. Large deletions and duplications in BRCA1 and BRCA2 are detected using multiplex PCR. Results of the test are used as an aid in identifying ovarian cancer patients with deleterious or suspected deleterious germline BRCA variants eligible for treatment with Lynparza™ (olaparib). This assay is for professional use only and is to be performed only at Myriad Genetic Laboratories, a single laboratory site located at 320 Wakara Way, Salt Lake City, UT 84108.
Lynparza is a trademark of AstraZeneca